Caris Life Sciences reported a 45% year-over-year jump in Q2 2026 revenue, driven primarily by molecular profiling services. The company also said it received its first Medicare reimbursement for its newly launched Caris ChromoSeq whole-genome sequencing and whole-transcriptome assay for myeloid malignancies. Caris CFO Luke Powers said the business is seeing growth from higher clinical case volume and average selling prices, while R&D services declined as the company pivots toward longer-term partnerships and pipeline expansion. The company outlined a version update to its MI Clarity cancer recurrence platform and a planned entry into the MRD space with a Caris MRD assay. For precision oncology stakeholders, the combination of reimbursement progress plus roadmap expansion underscores how assay workflows are translating into payor coverage and treatment decision integration.